Kimmerling Holdings Group, LLC Information

KHG FiteBac® Technology is an innovative biomedical company focused on fighting infectious diseases and microbial resistance through new FDA-approved, patented antimicrobial technology. -- FiteBac® Technology is presently in dental materials and will soon exist in wound care products, sutures, along with most every conceivable medical vinyl product, from endotracheal tubes, surgical gloves, catheters, blood bags, and eventually permanent body devices such as dental implants and orthopedic devices. -- Medical history can open a new chapter with the drug application of FiteBac® advanced antimicrobial technology. Scientific evidence of K21 in vitro efficacy has shown it to be effective against replication of enveloped and non-enveloped RNA/DNA viruses. K21 also has efficacy against fungi and bacteria, such as Staphylococcus aureus, Klebsiella, chlamydia, MRSA, CRE, MTB, E. coli, drug-resistant Mycobacterium tuberculosis, drug-resistant Klebsiella, and ruptures Clostridium difficile spores. -- KHG FiteBac® Technology was derived from dozens of global researchers, world-class academia, and former NIH. -- For more information and published research www.khgfitebac.com -- Advisory Board: Dr. Dharam V. Ablashi Arthur Fry Dr. Gerhard R. Krueger, MD Dr. Albert Ramon, PhD Dr. James R. Malcolm, MD Dr. Chris Recknor, MD